Sureda, Anna
André, Marc
Borchmann, Peter
da Silva, Maria G.
Gisselbrecht, Christian
Vassilakopoulos, Theodoros P.
Zinzani, Pier Luigi
Walewski, Jan
Funding for this research was provided by:
Millennium Pharmaceuticals Inc. (N/A)
Article History
Received: 19 August 2020
Accepted: 23 October 2020
First Online: 10 November 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: AS reports research funding from Roche; personal financial interests in Takeda, Gilead, Celgene, Novartis, and Kite Gilead; and receipt of other payments from: Takeda, BMS, MSD, Roche, Celgene, Janssen, Novartis, Kite Gilead, Sanofi, Daiichi, and GenMab. MA reports research funding and other payments from Takeda. PB reports receipt of research funding from Takeda Oncology. MS reports research funding form Gilead and receipt of other payments from: Roche, Celgene, Kite Gilead, and Abbvie. CG reports no conflicts of interest. TV reports receipt of other payments from BMS, Genesis Pharmaceuticals, Roche, Takeda, Novartis, Gilead, Merck, Astellas, and Winmedica. PLZ reports receipt of other payments from: MSD, Verastem, Roche, Servier, Celgene, Novartis, Gilead, BMS, Portola, Morphosys, Janssen, Hikma and Celltrion. JW reports research funding from: Roche, GSK, Novartis, Takeda, Janssen; and receipt of other payments from Roche, Celgene, Takeda, Janssen, Servier, Amgen, BMS, Abbvie, Novartis, and Gilead.